Literature DB >> 18290843

Gene-gene interaction between 14-3-3 zeta and butyrylcholinesterase modulates Alzheimer's disease risk.

I Mateo1, J Llorca, J Infante, E Rodríguez-Rodríguez, J Berciano, O Combarros.   

Abstract

A loss in the regulatory mechanism that controls tau phosphorylation in normal brain is suggested to cause tau hyperphosphorylation in Alzheimer's disease (AD) brain and the development of neurofibrillary tangles (NFT). 14-3-3 zeta protein and butyrylcholinesterase (BCHE) are associated with NFT in AD brain and stimulate tau phosphorylation. In a case-control study in 231 AD patients and 221 healthy controls, we examined whether the combined effects between 14-3-3 zeta (rs964917 and rs983583) and BCHE (K variant) polymorphisms might be responsible for susceptibility to AD. Subjects carrying both the BCHE K allele and the 14-3-3 zeta rs964917 G/G genotype (OR = 0.44, 95% CI = 0.20-0.95, P = 0.03), or 14-3-3 zeta rs983583 G/G genotype (OR = 0.46, 95% CI = 0.21-1.00, P = 0.05) had a lower risk of developing AD than subjects without these risk genotypes. Considering synergistic effects between polymorphisms in tau phosphorylation relate-genes may help in determining the risk profile for AD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18290843     DOI: 10.1111/j.1468-1331.2008.02059.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  9 in total

1.  Association of BDNF and BCHE with Alzheimer's disease: Meta-analysis based on 56 genetic case-control studies of 12,563 cases and 12,622 controls.

Authors:  Huihui Ji; Dongjun Dai; Yunliang Wang; Danjie Jiang; Xingyu Zhou; Peipei Lin; Xiaosui Ji; Jinfeng Li; Yuzheng Zhang; Honglei Yin; Rongrong Chen; Lina Zhang; Mingqing Xu; Shiwei Duan; Qinwen Wang
Journal:  Exp Ther Med       Date:  2015-03-03       Impact factor: 2.447

2.  14-3-3θ Does Not Protect against Behavioral or Pathological Deficits in Alzheimer's Disease Mouse Models.

Authors:  Mary Gannon; Bing Wang; Sara Anne Stringfellow; Stephan Quintin; Itzel Mendoza; Thanushri Srikantha; A Claire Roberts; Takashi Saito; Takaomi C Saido; Erik D Roberson; Talene A Yacoubian
Journal:  eNeuro       Date:  2022-06-24

3.  BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia.

Authors:  Alessandra Bizzarro; V Guglielmi; R Lomastro; A Valenza; A Lauria; C Marra; M C Silveri; F D Tiziano; C Brahe; C Masullo
Journal:  J Neural Transm (Vienna)       Date:  2010-03       Impact factor: 3.575

Review 4.  14-3-3 Proteins: Novel Pharmacological Targets in Neurodegenerative Diseases.

Authors:  F Sanders Pair; Talene A Yacoubian
Journal:  Trends Pharmacol Sci       Date:  2021-01-28       Impact factor: 14.819

5.  Concerted perturbation observed in a hub network in Alzheimer's disease.

Authors:  Dapeng Liang; Guangchun Han; Xuemei Feng; Jiya Sun; Yong Duan; Hongxing Lei
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

6.  Butyrylcholinesterase K variant and Alzheimer's disease risk: a meta-analysis.

Authors:  Zongcheng Wang; Yuren Jiang; Xi Wang; Yangsen Du; Dandan Xiao; Youchao Deng; Jinlian Wang
Journal:  Med Sci Monit       Date:  2015-05-16

7.  An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer's disease.

Authors:  Christopher Clark; Loïc Dayon; Mojgan Masoodi; Gene L Bowman; Julius Popp
Journal:  Alzheimers Res Ther       Date:  2021-04-01       Impact factor: 6.982

8.  Early increase of cerebrospinal fluid 14-3-3ζ protein in the alzheimer's disease continuum.

Authors:  Yuanyuan Lu
Journal:  Front Aging Neurosci       Date:  2022-07-29       Impact factor: 5.702

9.  Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease.

Authors:  Jakob M Bader; Philipp E Geyer; Johannes B Müller; Maximilian T Strauss; Manja Koch; Frank Leypoldt; Peter Koertvelyessy; Daniel Bittner; Carola G Schipke; Enise I Incesoy; Oliver Peters; Nikolaus Deigendesch; Mikael Simons; Majken K Jensen; Henrik Zetterberg; Matthias Mann
Journal:  Mol Syst Biol       Date:  2020-06       Impact factor: 11.429

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.